This Article Free Full Text Free Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Clarke, C. J. Articles by Haselden, J. N. Search for Related Content PubMed PubMed Citation Articles by Clarke, C. J. Articles by Haselden, J. N. Pubmed/NCBI databases Medline Plus Health Information Medicines Social Bookmarking                         What's this?

Metabolic Profiling as a Tool for Understanding Mechanisms of Toxicity

Novartis Pharma AG, Basel, Switzerland

Correspondence: Address correspondence to: Dr. Christopher J. Clarke, Novartis Pharma AG, Preclinical Safety, WKL-105.4.21, CH-4002 Basel, Switzerland; email: christopher.clarke{at}novartis.com.

Metabolic profiling (metabolomics/metabonomics) is the measurement in biological systems of the complement of low-molecular-weight metabolites and their intermediates that reflects the dynamic response to genetic modification and physiological, pathophysiological, and/or developmental stimuli. The measurement and interpretation of the endogenous metabolite profile from a biological sample (typically urine, serum, or biological tissue extract) have provided many opportunities to investigate the changes induced by external stimuli (e.g., drug treatment) or enhance our knowledge of inherent biological variation within subpopulations. This article will focus on the basic principles of metabolic profiling and how the tools (nuclear magnetic resonance [NMR], liquid chromatography–mass spectrometry [LC-MS]) can be applied in toxicology and pathology. Metabolic profiling can complement conventional methodologies and other "omics" technologies in investigating preclinical drug development issues. Case studies will illustrate the value of metabolic profiling in improving our understanding of phospholipidosis and peroxisome proliferation. A key message will be that metabolic profiling offers huge potential to highlight biomarkers and mechanisms in support of toxicology and pathology investigations in preclinical drug development.

Key Words: Metabonomics • preclinical safety assessment/risk management • pathobiology • biochemistry • biomarkers

Abbreviations: ACMSD, amino-carboxy-muconate-semialdehydedecarboxylase • CAD, cationic amphiphilic drug • CCR5, chemokine receptor 5 • CSF, cerebrospinal fluid • GC, gas chromatography • HP, high performance • HPLC, high performance liquid chromatography • LBPA, lyso-bis phosphatidic acid • LC, liquid chromatography • MS, mass spectrometry • NMN, N-methyl-nicotinamide • NMR, nuclear magnetic resonance • PAG, phenyl acetyl glycine • PCA, principal component analysis • PP, peroxisome proliferation • PPAR, peroxisome proliferator activated receptor • QAPRT, quinolate phosphorlbosyl-transferase • RT, real time • RT-PCR, reverse transcriptase polymerase chain reaction • TSP, 1,1,2,2-d4 trimethylsilylproprionate • UP, ultra performance • 4PY, N-methyl-4-pyridone-3-carboxamide

Toxicologic Pathology, Vol. 36, No. 1, 140-147 (2008)
DOI: 10.1177/0192623307310947


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?